The following is a reversible and selective MAO-A inhibitor: A. Bupropion B. Entacapone C. Moclobemide D. Selegiline

The following is a reversible and selective MAO-A
inhibitor:
A. Bupropion
B. Entacapone
C. Moclobemide
D. Selegiline
by

1 Answer

Answer :

C. Moclobemide
by

Related questions

Which of the following is a selective MAO-B inhibitor: A. Selegiline B. Clorgyline C. Moclobemide D. Tranylcypromine

Description : Which of the following is a selective MAO-B inhibitor: A. Selegiline B. Clorgyline C. Moclobemide D. Tranylcypromine

Last Answer : A. Selegiline

Choose the correct statement about moclobemide: A. It is a reversible inhibitor of MAO-A with short duration of action B. Patients taking it need to be cautioned not to consume tyramine rich food C. It is contraindicated in elderly patients D. It produces anticholinergic side effect

Description : Choose the correct statement about moclobemide: A. It is a reversible inhibitor of MAO-A with short duration of action B. Patients taking it need to be cautioned not to consume tyramine rich food C. It is contraindicated in elderly patients D. It produces anticholinergic side effect

Last Answer : A. It is a reversible inhibitor of MAO-A with short duration of action

Which of the following MAO inhibitors is most likely to produce cheese reaction: A. Tranylcypromine B. Moclobemide C. Selegiline D. Clorgyline

Description : Which of the following MAO inhibitors is most likely to produce cheese reaction: A. Tranylcypromine B. Moclobemide C. Selegiline D. Clorgyline

Last Answer : A. Tranylcypromine

Which of the following is labelled as a 'serotonin and noradrenaline reuptake inhibitor or SNRI': A. Amineptine B. Venlafaxine C. Bupropion D. Citalopram

Description : Which of the following is labelled as a 'serotonin and noradrenaline reuptake inhibitor or SNRI': A. Amineptine B. Venlafaxine C. Bupropion D. Citalopram

Last Answer : D. Citalopram

The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Description : The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Last Answer : A. α-methyl-p-tyrosine

In a comatose patient suspected of poisoning, which of the following findings would be against the drug being morphine (a) Selegiline (b) Chlorgiline (c) Moclobemide (d) Tranylcypromine

Description : In a comatose patient suspected of poisoning, which of the following findings would be against the drug being morphine (a) Selegiline (b) Chlorgiline (c) Moclobemide (d) Tranylcypromine

Last Answer : Ans: A

The following category of drugs is not indicated in early/mild cases of Parkinson's disease: A. Central anticholinergic B. MAO-B inhibitor C. COMT inhibitor D. Nonergoline dopaminergic agonist

Description : The following category of drugs is not indicated in early/mild cases of Parkinson's disease: A. Central anticholinergic B. MAO-B inhibitor C. COMT inhibitor D. Nonergoline dopaminergic agonist

Last Answer : C. COMT inhibitor

The following is true of rivastigmine except: A. It is a relatively selective inhibitor of G1 isoform of acetylcholinesterase B. It has been found to retard disease progression in Alzheimer's disease C. It affords measurable improvement in Alzheimer's disease symptom score D. It enhances cerebral cholinergic transmission with only mild peripheral effect

Description : The following is true of rivastigmine except: A. It is a relatively selective inhibitor of G1 isoform of acetylcholinesterase B. It has been found to retard disease progression in ... 's disease symptom score D. It enhances cerebral cholinergic transmission with only mild peripheral effect

Last Answer : B. It has been found to retard disease progression in Alzheimer's disease

Choose the selective serotonin reuptake inhibitor that is less likely to inhibit CYP2D6 and CYP3A4 resulting in fewer drug interactions: A. Sertraline B. Paroxetine C. Fluoxetine D. Fluvoxamine

Description : Choose the selective serotonin reuptake inhibitor that is less likely to inhibit CYP2D6 and CYP3A4 resulting in fewer drug interactions: A. Sertraline B. Paroxetine C. Fluoxetine D. Fluvoxamine

Last Answer : A. Sertraline

The preferred class of drugs for long term treatment of severe anxiety disorder with intermittent panic attacks is: A. Phenothiazine (chlorpromazine like) B. Azapirone (buspirone like) C. β-blocker (propranolol like) D. Selective serotonin reuptake inhibitor (sertraline like)

Description : The preferred class of drugs for long term treatment of severe anxiety disorder with intermittent panic attacks is: A. Phenothiazine (chlorpromazine like) B. Azapirone (buspirone like) C. β-blocker (propranolol like) D. Selective serotonin reuptake inhibitor (sertraline like)

Last Answer : DD. Selective serotonin reuptake inhibitor (sertraline like)

Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α-reductase inhibitor used to reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Description : Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α- ... reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Last Answer : A. It is a PGF2α derivative used in glaucoma

Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α-reductase inhibitor used to reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Description : Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α- ... reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Last Answer : A. It is a PGF2α derivative used in glaucoma

The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Description : The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Last Answer : A. α-methyl-p-tyrosine

Prolonged painful erection of penis has been noted particularly as a side effect of: A. Doxepin B. Citalopram C. Bupropion D. Trazodone

Description : Prolonged painful erection of penis has been noted particularly as a side effect of: A. Doxepin B. Citalopram C. Bupropion D. Trazodone

Last Answer : D. Trazodone

The following is true of bupropion except: A. It inhibits dopamine reuptake along with inhibiting noradrenaline reuptake B. It produces sedation as a side effect C. It is being used as an aid for smoking cessation D. It is likely to produce seizures in overdose

Description : The following is true of bupropion except: A. It inhibits dopamine reuptake along with inhibiting noradrenaline reuptake B. It produces sedation as a side effect C. It is being used as an aid for smoking cessation D. It is likely to produce seizures in overdose

Last Answer : B. It produces sedation as a side effect

Select the drug that reversibly inhibits the enzyme COMT and is useful as an adjuvant medication in advanced parkinson's disease: A. Pramipexole B. Entacapone C. Pergolide D. Piribedil

Description : Select the drug that reversibly inhibits the enzyme COMT and is useful as an adjuvant medication in advanced parkinson's disease: A. Pramipexole B. Entacapone C. Pergolide D. Piribedil

Last Answer : B. Entacapone

The following is true about entacapone except: A. It acts by inhibiting degradation of dopamine in the brain B. If prolongs the therapeutic effect of levodopacarbidopa in parkinsonism C. It can accentuate levodopa induced dyskinesias D. It can cause diarrhoea as a side effec

Description : The following is true about entacapone except: A. It acts by inhibiting degradation of dopamine in the brain B. If prolongs the therapeutic effect of levodopacarbidopa in parkinsonism C. It can accentuate levodopa induced dyskinesias D. It can cause diarrhoea as a side effec

Last Answer : A. It acts by inhibiting degradation of dopamine in the brain

Entacapone differs from tolcapone in the following respect/respects: A. It is shorter acting B. It acts only by inhibiting peripheral metabolism of levodopa C. It is not hepatotoxic D. All of the above are correct

Description : Entacapone differs from tolcapone in the following respect/respects: A. It is shorter acting B. It acts only by inhibiting peripheral metabolism of levodopa C. It is not hepatotoxic D. All of the above are correct

Last Answer : D. All of the above are correct

The primary action by which entacapone and tolcapone enhance the therapeutic effect of levodopa-carbidopa in parkinsonism is: A. Inhibition of levodopa methylation in the liver B. Inhibition of dopamine methylation in the brain C. Inhibition of oxidative deamination of dopamine in the brain D. Facilitation of active transport of levodopa across brain capillaries

Description : The primary action by which entacapone and tolcapone enhance the therapeutic effect of levodopa-carbidopa in parkinsonism is: A. Inhibition of levodopa methylation in the liver B. Inhibition of ... of dopamine in the brain D. Facilitation of active transport of levodopa across brain capillaries

Last Answer : A. Inhibition of levodopa methylation in the liver

The following drug is effective in chlorpromazine induced parkinsonism: A. Trihexyphenidyl B. Selegiline C. Bromocriptine D. Levodopa + carbidopa

Description : The following drug is effective in chlorpromazine induced parkinsonism: A. Trihexyphenidyl B. Selegiline C. Bromocriptine D. Levodopa + carbidopa

Last Answer : A. Trihexyphenidyl

Which of the following drugs has mild antiparkinsonian action of its own, prolongs levodopa action and allows reduction of its dose by about 25%: A. Benserazide B. Selegiline C. Amantadine D. Pyridoxine

Description : Which of the following drugs has mild antiparkinsonian action of its own, prolongs levodopa action and allows reduction of its dose by about 25%: A. Benserazide B. Selegiline C. Amantadine D. Pyridoxine

Last Answer : B. Selegiline

The following is true of selegiline: A. It does not exert antiparkinsonian action unless combined with levodopa B. It overcomes the ‘on-off ’ effect in levodopa treated advanced parkinsonian patients C. It retards the progression of Parkinson's disease D. At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Description : The following is true of selegiline: A. It does not exert antiparkinsonian action unless combined with levodopa B. It overcomes the on-off ' effect in levodopa treated advanced parkinsonian ... D. At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Last Answer : . At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

The following drug is added to levodopa therapy of parkinsonism to attenuate ‘wearing off’ effect: A. Selegiline B. Trihexiphenidyl C. Amantadine D. Any of the abov

Description : The following drug is added to levodopa therapy of parkinsonism to attenuate ‘wearing off’ effect: A. Selegiline B. Trihexiphenidyl C. Amantadine D. Any of the abov

Last Answer : A. Selegiline

The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is: A. Carbidopa B. Amantadine C. Selegiline D. Bromocriptine

Description : The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is: A. Carbidopa B. Amantadine C. Selegiline D. Bromocriptine

Last Answer : C. Selegiline

The most effective drug in parkinsonism is: A. Bromocriptine B. Selegiline C. Levodopa + carbidopa D. Biperiden

Description : The most effective drug in parkinsonism is: A. Bromocriptine B. Selegiline C. Levodopa + carbidopa D. Biperiden

Last Answer : C. Levodopa + carbidopa

Which of the following is a valid therapeutic use of interaction? A. Use of Probenecid with Penicillin B. Giving Aspirin with warfarin C. Instructing patient to take levofloxacin with milk or antacid D. Treatment of depression of MAO Inhibitor and Citalopram

Description : Which of the following is a valid therapeutic use of interaction? A. Use of Probenecid with Penicillin B. Giving Aspirin with warfarin C. Instructing patient to take levofloxacin with milk or antacid D. Treatment of depression of MAO Inhibitor and Citalopram

Last Answer : A. Use of Probenecid with Penicillin 

Cheese reaction' in a MAO inhibited patient manifests as: A. Precipitous fall in blood pressure and shock B. Hypertensive crisis C. Acute manic episode D. Convulsions

Description : Cheese reaction' in a MAO inhibited patient manifests as: A. Precipitous fall in blood pressure and shock B. Hypertensive crisis C. Acute manic episode D. Convulsions

Last Answer : A. Precipitous fall in blood pressure and shock

The nonselective MAO inhibitors are not used clinically as antidepressants because of their: A. Low antidepressant efficacy B. Higher toxicity C. Potential to interact with many foods and drugs D. Both 'B' and 'C' are correct

Description : The nonselective MAO inhibitors are not used clinically as antidepressants because of their: A. Low antidepressant efficacy B. Higher toxicity C. Potential to interact with many foods and drugs D. Both 'B' and 'C' are correct

Last Answer : D. Both 'B' and 'C' are correct

Monitoring plasma drug concentration is useful while using: A. Antihypertensive drugs B. Levodopa C. Lithium carbonate D. MAO inhibitors

Description : Monitoring plasma drug concentration is useful while using: A. Antihypertensive drugs B. Levodopa C. Lithium carbonate D. MAO inhibitors

Last Answer : C. Lithium carbonate

The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Description : The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Last Answer : C. Axonal uptake

Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Last Answer : C. By a nonexocytotic process

Selective serotonin reuptake inhibitor is (A) Imipramine (B) Iproniazide (C) Fluoxetin (D)Naphazoline

Description : Selective serotonin reuptake inhibitor is (A) Imipramine (B) Iproniazide (C) Fluoxetin (D)Naphazoline

Last Answer : (C) Fluoxetin

In reversible non-competitive enzyme activity inhibition (A) Inhibitor bears structural resemblance to substrate (B) Inhibitor lowers the maximum velocity attainable with a given amount of enzyme (C) Km is increased (D) Km is decreased

Description : In reversible non-competitive enzyme activity inhibition (A) Inhibitor bears structural resemblance to substrate (B) Inhibitor lowers the maximum velocity attainable with a given amount of enzyme (C) Km is increased (D) Km is decreased

Last Answer : Answer : B

Which of the following is a reversible inhibitor of platelet cyclooxygenase? (a) Alprostadil (b) Aspirin (c) Ibuprofen (d) LTC4 (e) Misoprostol

Description : Which of the following is a reversible inhibitor of platelet cyclooxygenase? (a) Alprostadil (b) Aspirin (c) Ibuprofen (d) LTC4 (e) Misoprostol

Last Answer : Ans: C

Choose the correct statement about topotecan: A. It is a DNA topoisomerase I inhibitor which causes single strand DNA breaks B. It is a cell cycle specific anticancer drug C. It is a COMT-inhibitor used in advanced parkinsonism D. Both 'A' and 'B' are correc

Description : Choose the correct statement about topotecan: A. It is a DNA topoisomerase I inhibitor which causes single strand DNA breaks B. It is a cell cycle specific anticancer drug C. It is a COMT-inhibitor used in advanced parkinsonism D. Both 'A' and 'B' are correc

Last Answer : D. Both 'A' and 'B' are correct

The following antineoplastic drug is a mitotic inhibitor and causes metaphase arrest: A. Busulfan B. Vincristine C. Cytarabine D. Procarbazine

Description : The following antineoplastic drug is a mitotic inhibitor and causes metaphase arrest: A. Busulfan B. Vincristine C. Cytarabine D. Procarbazine

Last Answer : B. Vincristine

The initial regimen for antiretroviral therapy of previously untreated HIV patient consist of: A. Two nucleoside reverse transcriptase inhibitors (NRTIs) + one protease inhibitor (PI) B. Two NRTIs + one non-NRTI C. Three NRTIs D. Any of the above

Description : The initial regimen for antiretroviral therapy of previously untreated HIV patient consist of: A. Two nucleoside reverse transcriptase inhibitors (NRTIs) + one protease inhibitor (PI) B. Two NRTIs + one non-NRTI C. Three NRTIs D. Any of the above

Last Answer : D. Any of the above

ndicate the anti-HIV regimen that is generally reserved for advanced cases of AIDS or for repeated treatment failures: A. Two nucleoside reverse transcriptase inhibitors (NRTIs) + one protease inhibitor (PI) B. Three NRTIs C. Two NRTIs + one non-NRTI D. One NRTI + one non-NRTI + one PI

Description : ndicate the anti-HIV regimen that is generally reserved for advanced cases of AIDS or for repeated treatment failures: A. Two nucleoside reverse transcriptase inhibitors (NRTIs) + one protease inhibitor (PI) B. Three NRTIs C. Two NRTIs + one non-NRTI D. One NRTI + one non-NRTI + one PI

Last Answer : D. One NRTI + one non-NRTI + one PI

Fluconazole differs from ketoconazole in that: A. It is not active by the oral route B. It is a more potent inhibitor of drug metabolism C. It is not effective in cryptococcal meningitis D. It is unlikely to produce anti-androgenic side effects

Description : Fluconazole differs from ketoconazole in that: A. It is not active by the oral route B. It is a more potent inhibitor of drug metabolism C. It is not effective in cryptococcal meningitis D. It is unlikely to produce anti-androgenic side effects

Last Answer : D. It is unlikely to produce anti-androgenic side effects

Sulbactam differs from clavulanic acid in that: A. It is not a progressive inhibitor of β-lactamase B. It does not inhibit β-lactamase produced by gram negative bacilli C. It is quantitatively more potent D. It per se inhibits N.gonorrhoeae

Description : Sulbactam differs from clavulanic acid in that: A. It is not a progressive inhibitor of β-lactamase B. It does not inhibit β-lactamase produced by gram negative bacilli C. It is quantitatively more potent D. It per se inhibits N.gonorrhoeae

Last Answer : D. It per se inhibits N.gonorrhoeae

The following statement is not true of sulbactam: A. It is a broad spectrum β-lactamase inhibitor B. It does not augment the activity of ampicillin against bacteria that are sensitive to the latter C. It induces chromosomal β-lactamases D. Combined with ampicillin, it is highly effective against penicillinase producing N. gonorrhoeae

Description : The following statement is not true of sulbactam: A. It is a broad spectrum β-lactamase inhibitor B. It does not augment the activity of ampicillin against bacteria that are sensitive ... β-lactamases D. Combined with ampicillin, it is highly effective against penicillinase producing N. gonorrhoeae

Last Answer : C. It induces chromosomal β-lactamases

Select the drug which is an inhibitor of gastric mucosal proton pump: A. Carbenoxolone sodium B. Sucralfate C. Famotidine D. Lansoprazole

Description : Select the drug which is an inhibitor of gastric mucosal proton pump: A. Carbenoxolone sodium B. Sucralfate C. Famotidine D. Lansoprazole

Last Answer : D. Lansoprazole

Choose the correct statement about lovastatin: A. It markedly lowers plasma triglyceride with little effect on cholesterol level B. It is used as an adjuvant to gemfibrozil for type III hyperlipoproteinemia C. It is not effective in diabetes associated hypercholesterolemia D. It is a competitive inhibitor of the rate limiting step in cholesterol synthesis

Description : Choose the correct statement about lovastatin: A. It markedly lowers plasma triglyceride with little effect on cholesterol level B. It is used as an adjuvant to gemfibrozil for type III ... hypercholesterolemia D. It is a competitive inhibitor of the rate limiting step in cholesterol synthesis

Last Answer : D. It is a competitive inhibitor of the rate limiting step in cholesterol synthesis

Features of atorvastatin include the following: A. Dose to dose most potent HMG-CoA reductase inhibitor B. Higher ceiling of LDL-cholesterol lowering action than lovastatin C. Antioxidant property D. All of the above

Description : Features of atorvastatin include the following: A. Dose to dose most potent HMG-CoA reductase inhibitor B. Higher ceiling of LDL-cholesterol lowering action than lovastatin C. Antioxidant property D. All of the above

Last Answer : D. All of the above

Select the most appropriate hypolipidemic drug for a patient with raised LDL-cholesterol level but normal triglyceride level: A. A HMG-CoA reductase inhibitor B. A fibric acid derivative C. Gugulipid D. Nicotinic acid

Description : Select the most appropriate hypolipidemic drug for a patient with raised LDL-cholesterol level but normal triglyceride level: A. A HMG-CoA reductase inhibitor B. A fibric acid derivative C. Gugulipid D. Nicotinic acid

Last Answer : A. A HMG-CoA reductase inhibitor

Choose the most potent and most efficacious LDLcholesterol lowering HMG-CoA reductase inhibitor: A. Lovastatin B. Simvastatin C. Pravastatin D. Atorvastatin

Description : Choose the most potent and most efficacious LDLcholesterol lowering HMG-CoA reductase inhibitor: A. Lovastatin B. Simvastatin C. Pravastatin D. Atorvastatin

Last Answer : D. Atorvastatin

The following type of vasodilator is not beneficial in CHF due to systolic dysfunction: A. Calcium channel blocker B. Angiotensin converting enzyme inhibitor C. Nitrate D. Hydralazine

Description : The following type of vasodilator is not beneficial in CHF due to systolic dysfunction: A. Calcium channel blocker B. Angiotensin converting enzyme inhibitor C. Nitrate D. Hydralazine

Last Answer : A. Calcium channel blocker

A patient of CHF was treated with furosemide and digoxin. He became symptom-free and is stable for the last 3 months with resting heart rate 68/min in sinus rhythm but left ventricular ejection fraction is low. Which of the following lines of action is warranted: A. Stop above medication and start an ACE inhibitor B. Continue all medication as before C. Continue the diuretic but stop digoxin D. Continue digoxin but stop the diuretic

Description : A patient of CHF was treated with furosemide and digoxin. He became symptom-free and is stable for the last 3 months with resting heart rate 68/min in sinus rhythm but left ventricular ... medication as before C. Continue the diuretic but stop digoxin D. Continue digoxin but stop the diuretic

Last Answer : A. Stop above medication and start an ACE inhibitor

Long term ACE inhibitor therapy may retard the progression of: A. Diabetic nephropathy B. Diabetic retinopathy C. Hypertensive nephropathy D. All of the above

Description : Long term ACE inhibitor therapy may retard the progression of: A. Diabetic nephropathy B. Diabetic retinopathy C. Hypertensive nephropathy D. All of the above

Last Answer : D. All of the above